BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/28/2019 12:22:27 PM | Browse: 900 | Download: 1225
 |
Received |
|
2019-03-30 04:35 |
|
Peer-Review Started |
|
2019-04-01 07:18 |
|
To Make the First Decision |
|
2019-04-17 00:18 |
|
Return for Revision |
|
2019-04-17 02:54 |
|
Revised |
|
2019-04-24 23:05 |
|
Second Decision |
|
2019-05-17 09:09 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-05-18 12:42 |
|
Articles in Press |
|
2019-05-18 12:42 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-06-27 08:28 |
|
Publish the Manuscript Online |
|
2019-06-28 12:22 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected byan in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Immunotherapy for hepatocellular carcinoma: Current and future
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Michael P Johnston and Salim I Khakoo |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Salim I Khakoo, FRCP (C), MBBS, MD, Professor, Department of Clinical and Experimental Sciences, Faculty of Medicine, Southampton General Hospital, University of Southampton, Mailpoint 811, Level E South Academic Block, Tremona Road, Southampton SO16 6YD, United Kingdom. s.i.khakoo@soton.ac.uk |
| Key Words |
Adoptive cell therapy; Cancer vaccine; Checkpoint inhibitor; Hepatocellular carcinoma; Immunotherapy; Liver cancer; Oncolytic virus |
| Core Tip |
A significant proportion of patients with hepatocellular carcinoma (HCC) present with advanced disease, for which there are limited systemic therapeutic options. Complicating this, HCC often develops on a background of cirrhosis, which can preclude the use of certain cytotoxic agents. Immunotherapy has previously not been an available therapeutic option in HCC. However, checkpoint inhibition therapy was recently licensed as a second line option for advanced disease. Multiple other promising agents are in development which boost existing immune response or stimulate a de novo immune response. These agents are discussed herein. |
| Publish Date |
2019-06-28 12:22 |
| Citation |
Johnston MP, Khakoo SI. Immunotherapy for hepatocellular carcinoma: Current and future. World J Gastroenterol 2019; 25(24): 2977-2989 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i24/2977.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i24.2977 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
